Suzanne Farid
 | This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (April 2024) |
Suzanne Farid | |
|---|---|
| Occupation | Engineer |
| Engineering career | |
| Discipline | Biochemical Engineering |
| Institutions | University College London |
Suzanne Farid is an engineer who specialises in Biochemical and Systems Engineering. She currently serves as a professor at University College London.
Career[edit]
Farid's career has focused on researching and developing monoclonal antibodies to cell and gene therapies. In 2007, Farid's paper featured in the Journal of Chromatography discussing the cost-effective manufacture of antibodies.[1]
She featured in Biotechnology and Bioengineering in 2012, with Farid evaluating current and future potential of batch and continuous cell culture technologies. The paper followed a case study into the commercial manufacture of monoclonal antibodies.[2]
In 2020, Farid and lead-author Maria Papathanasiou published a paper in Nature on how T cells could be used as a cancer therapy in the future.[3][4] Her expertise in the field led her to be part of the government task force during the COVID-19 pandemic as a member of the 100 Days Mission roundtable. Farid was also interviewed numerous times in relation to the development of a vaccine and also became Director of the UCL-AstraZeneca Bioprocessing Centre of Excellence.[5]
In 2022, she was elected as a fellow at the Royal Academy of Engineering.[6][7] She also serves as co-director of the Future Targeted Healthcare Manufacturing Hub, which is funded by the Engineering and Physical Sciences Research Council.[8]
References[edit]
- ^ "Process economics of industrial monoclonal antibody manufacture". Journal of Chromatography.
- ^ "Fed-batch and perfusion culture processes: Economic, environmental, and operational feasibility under uncertainty". Biotechnology and Bioengineering.
- ^ "Autologous CAR T-cell therapies supply chain: challenges and opportunities?". Nature.
- ^ West, Sara (February 17, 2020). "Engineering solutions to improve access to autologous CAR-T cell therapy". Imperial College London.
- ^ Furlong, Ashleigh (July 18, 2020). "Europe's challenge of a lifetime: Manufacturing enough coronavirus vaccines". Politico.
- ^ Hebden, Kerry. "New RAEng Fellows includes three IChemE members". The Chemical Engineer.
- ^ "IChemE Fellows elected to the Royal Academy of Engineering". Institution of Chemical Engineers. September 20, 2023.
- ^ "Future Targeted Healthcare Manufacturing Hub". University College London.
External links[edit]
| Authority control databases: Academics |
|---|